Comparing SG&A Expenses: TG Therapeutics, Inc. vs Vericel Corporation Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. This analysis compares the SG&A trends of TG Therapeutics, Inc. and Vericel Corporation from 2014 to 2023. Over this period, TG Therapeutics saw a dramatic increase in SG&A expenses, peaking in 2021 with a 1,200% rise from 2014. Meanwhile, Vericel Corporation experienced a steady climb, with expenses growing by approximately 780% over the same period. Notably, both companies reached their highest SG&A expenses in 2023, with TG Therapeutics at $122 million and Vericel at $121 million. This trend highlights the escalating costs associated with scaling operations and expanding market reach in the biotech sector. Understanding these financial dynamics is essential for investors and stakeholders aiming to navigate the complexities of the industry.